CAROLYN SUSCA: Open Payments
NPI 1205593951 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,967 in 106 payments from 15 companies in 2025. Trend: 2023 $1,714 · 2024 $3,569 · 2025 $1,967
Food & beverage: $1,967
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $315 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $257 |
| Janssen Biotech, Inc. | 17 | $237 |
| Madrigal Pharmaceuticals | 7 | $236 |
| Phathom Pharmaceuticals, Inc. | 8 | $207 |
| Gilead Sciences, Inc. | 11 | $183 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 10 | $173 |
| Lilly USA, LLC | 5 | $84 |
| Celltrion USA Inc. | 3 | $65 |
| Ipsen Biopharmaceuticals, Inc | 4 | $63 |
Products named: TREMFYA, REZDIFFRA, VOQUEZNA, XIFAXAN, ENTYVIO, RINVOQ, LINZESS, OMVOH.
Industry payments across TX — which companies pay providers there.
